First-in-class therapy for a worldwide market
We are thrilled to announce our ground breaking Phase II results published in Addiction Journal (April 10th 2024) entitled: Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial. https://onlinelibrary.wiley.com/doi/10.1111/add.16484 The article demonstrates
Kinnov Therapeutics received the authorization to test KT-110 for clinical pharmacokinetics of once daily on 8 subjects in France.
ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) is the french Drug Regulatory Authority.
Through review of Kinnov phase 2 trial results, and interview with Henri-Jean Aubin, Alain Puech and Emmanuel de Rivoire, Outsourcing-Pharma shares an article providing key answers as to why people affected with AUD could see their alcohol intake reduced by
CORDIS platform shares results of Kinnov projects funded by European Commission within the scope of the Horizon 2020 program: https://cordis.europa.eu/project/id/873252/reporting/fr CORDIS is the main source of results of European Commission’s innovation and research funding programs. Horizon 2020 is the funding
Kinnov Therapeutics will be present at the 29th annual BIO-Europe congress BIO-Europe | Meet dealmakers from biotech, pharma and finance (informaconnect.com), in Munich on November 6, 7 and 8, 2023.
![Alcohol dependency: in a phase 2 clinical trial, a combination of drugs gave a better results than current medications [article in French]…](https://www.kinnov-therapeutics.com/wp-content/uploads/2023/10/Alcohol-dependency-in-a-phase-2-clinical-trial-a-combination-of-drugs-gave-a-better-results-than-current-medications-article-in-French…-750x350.jpg "Alcohol dependency: in a phase 2 clinical trial, a combination of drugs gave a better results than current medications [article in French]…")
A phase 2 trial based on the simultaneous blockade of two neurobiological pathways has shown exciting results in patients with severe alcohol use disorder. Actualités Medscape, 23 juin 2022
Un essai de phase 2 reposant sur le blocage simultané de deux voies neurobiologiques a obtenu des résultats enthousiasmants chez des patients atteints d’un trouble sévère de l’usage de l’alcool. Actualités Medscape, 23 juin 2022
Kinnov-Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder. Kinnov-Therapeutics has reached a key clinical milestone for treatment of Alcohol Use Disorder with a Phase 2 clinical study for its game changing drug
Kinnov-Therapeutics will be present at the 16th International Congress of Addictology of the Albatros in Paris on June 7, 8 and 9, 2022. Two conferences will be given: one, presenting the “Cocktail” study, a randomized, placebo-controlled proof-of-concept phase 2 trial,
Cliquer ici pour accéder à l’article dans La République du Centre.